Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients
Crossref DOI link: https://doi.org/10.1186/s13054-017-1798-7
Published Online: 2017-08-15
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Russell, James A.
Vincent, Jean-Louis
Kjølbye, Anne Louise
Olsson, Håkan
Blemings, Allan
Spapen, Herbert
Carl, Peder
Laterre, Pierre-Francois
Grundemar, Lars
Funding for this research was provided by:
Ferring